Cardiol Therapeutics Inc Class A saw a notable increase, closing up 4.08% in the latest trading session.
In a positive turn for investors, Cardiol Therapeutics Inc Class A (CRDL.TO) rose by 4.08% today, closing at CA$1.53. This increase comes as the company makes progress in its clinical trials and strategic efforts to grow its market presence.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$165.99M
52W high
$2.33
52W low
$1.23
1W change
-1.96%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 300.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+300.0% Upside
Current Price
C$1.50
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
35.1%
Annualized
90-Day Vol
58.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.25
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.41 | C$1.25 โ C$1.60 |
| 60 trading days | C$1.33 | C$1.12 โ C$1.58 |
| 90 trading days | C$1.25 | C$1.02 โ C$1.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The recent performance of Cardiol Therapeutics signals potential growth in the biotech sector, especially as the company advances its clinical programs and connects with the investment community.
4.08% Increase in Stock Price
Cardiol Therapeutics Inc Class A's stock climbed to CA$1.53, reflecting investor optimism amid ongoing clinical developments.
Bull case
The recent rise in Cardiol's stock price shows growing investor confidence, especially after the acceptance of its Phase II MAvERIC results for publication in a respected journal. This could boost the companyโs credibility and attract more investment.
Bear case
Even with the positive movement, investors should stay cautious. Cardiol Therapeutics has yet to establish a steady revenue stream, and the biotech sector can be unpredictable, heavily influenced by the outcomes of clinical trials and overall market sentiment.
Recent Developments Fueling Growth
Cardiol Therapeutics recently announced that the results from its Phase II MAvERIC trial were accepted for publication in the Journal of the American Heart Association. This is a significant milestone that could enhance the company's visibility and credibility in the medical community, potentially drawing in more investors. Additionally, expanding its U.S. MAVERIC Phase III trial network indicates growing interest in its key programs, which could further boost stock performance. For more details, visit our Cardiol Therapeutics stock page.
Market Confidence and Future Prospects
The rise in Cardiol's stock price reflects a broader confidence in the biotech sector, especially as companies like Cardiol continue to innovate. Investors should consider the implications of ongoing clinical trials and the potential for future partnerships or financing rounds. As Cardiol Therapeutics works to extend its cash runway and develop its product pipeline, the stock may offer growth opportunities. Keep an eye on updates via our CRDL.TO page.
Advertisement
